Atlas Venture Life Science Advisors

Latest statistics and disclosures from Atlas Venture Life Science Advisors's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are KYMR, DYN, SION, Kailera Therapeutics, IRON, and represent 94.63% of Atlas Venture Life Science Advisors's stock portfolio.
  • Added to shares of these 2 stocks: Kailera Therapeutics (+$114M), QTTB (+$8.0M).
  • Started 1 new stock position in Kailera Therapeutics.
  • Reduced shares in these 3 stocks: KYMR (-$198M), DYN (-$52M), KRRO.
  • Atlas Venture Life Science Advisors was a net seller of stock by $-131M.
  • Atlas Venture Life Science Advisors has $881M in assets under management (AUM), dropping by 11.55%.
  • Central Index Key (CIK): 0001917529

Tip: Access up to 7 years of quarterly data

Positions held by Atlas Venture Life Science Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Atlas Venture Life Science Advisors

Atlas Venture Life Science Advisors holds 7 positions in its portfolio as reported in the June 2026 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Kymera Therapeutics Common Stock (KYMR) 37.1 $327M -37% 2.8M 114.67
 View chart
Dyne Therapeutics Common Stock (DYN) 17.1 $151M -25% 6.8M 22.21
 View chart
Sionna Therapeutics Common Stock (SION) 15.0 $132M 3.0M 43.99
 View chart
Kailera Therapeutics Common Stock 12.9 $114M NEW 5.2M 22.03
 View chart
Disc Medicine Common Stock (IRON) 12.6 $111M 1.5M 73.14
 View chart
Q32 Bio Common Stock (QTTB) 3.9 $35M +29% 2.7M 12.74
 View chart
Korro Bio Common Stock (KRRO) 1.4 $13M -15% 963k 13.18
 View chart

Past Filings by Atlas Venture Life Science Advisors

SEC 13F filings are viewable for Atlas Venture Life Science Advisors going back to 2022

View all past filings